Form 4: Athira Pharma Director Joseph Edelman Granted 20,900 Stock Options

Joseph Edelman, a Director and 10% Owner of Athira Pharma, Inc., was granted 20,900 stock options as part of the company's Outside Director Compensation Policy.

Summary

• Joseph Edelman, a Director and 10% Owner of Athira Pharma, Inc. (ATHA), acquired 20,900 stock options on May 30, 2025.
• The options have an exercise price of $0.3125 per share and an expiration date of May 29, 2035.
• The shares underlying the option will vest on the earlier of May 30, 2026, or the day immediately before the next annual meeting of the Issuer's stockholders that occurs after May 30, 2025.
• This grant was made pursuant to the terms of Athira Pharma's Outside Director Compensation Policy.
• Following this transaction, Mr. Edelman beneficially owns 20,900 derivative securities directly.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. This is a routine compensation event that aligns director interests with shareholders, which is generally viewed favorably, but it does not indicate any new operational or financial performance.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing long-term company performance.
• The transaction is part of a pre-established compensation policy, indicating a structured approach to director remuneration.

Future Outlook

The granted stock options are subject to a future vesting schedule, which will occur on the earlier of May 30, 2026, or the day before the next annual meeting of stockholders after May 30, 2025.

Industry Context

The grant of stock options to outside directors is a common practice across various industries, including biotechnology and pharmaceuticals, to attract and retain qualified board members and align their incentives with company performance.

Comparison to Industry Standards

• Granting stock options as part of director compensation is a standard practice in publicly traded companies, comparable to compensation structures seen in other biotech firms.
• The vesting schedule, tied to a specific date or the next annual meeting, is also a common mechanism to ensure continued engagement and long-term commitment from board members.

Corporate Governance

Related Party Transactions

• The grant of stock options to Joseph Edelman, a Director and 10% Owner, constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with long-term shareholder value creation.
• Management: The compensation policy supports the retention of experienced board members who can provide strategic oversight.

Next Steps

• The stock options will vest on the earlier of May 30, 2026, or the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 30, 2025.

Key Dates

Keywords

Athira Pharma, ATHA, Joseph Edelman, Stock Option, Director Compensation, Insider Transaction, SEC Form 4, Beneficial Ownership